This page shows the latest Zinbryta news and features for those working in and with pharma, biotech and healthcare.
Biogen and AbbVie have voluntarily withdrawn their multiple sclerosis drug Zinbryta from the market worldwide, saying the move is in the best interests of patients. ... The EMA recommends that doctors should review patients currently treated with
remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).
NICE turned down Zinbryta in draft guidance issued last October, criticising the analysis submitted by Biogen of the cost effectiveness of daclizumab compared with other disease-modifying treatments. ... Zinbryta is also being considered for use by the
recently-approved Zinbryta (daclizumab) and bringing forward phase III Alzheimer's disease candidate aducanumab.
Vounatsos highlighted the prospects for just-approved Zinbryta (daclizumab), a once-monthly MS therapy which is due for launch in the US and Germany next month, as well as the
If approved Ocrevus will compete for MS market share with Biogen's recently-approved Zinbryta, while Novartis has an anti-B cell candidate in its pipeline, which the company claims has
More from news
Approximately 6 fully matching, plus 1 partially matching documents found.
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...